NCT06078722 is a clinical trial in Metabolic-associated Fatty Liver Disease (MAFLD), sponsored by Kazakh Association of Internal Medicine Specialists.

Who is sponsoring NCT06078722?

NCT06078722 is sponsored by Kazakh Association of Internal Medicine Specialists.

What condition does NCT06078722 study?

NCT06078722 studies Metabolic-associated Fatty Liver Disease (MAFLD).

Is NCT06078722 still recruiting?

NCT06078722 is currently status unknown. Last updated 12 October 2023.

Last reviewed 2023-10-12 · How we verify

NCT06078722

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of the Effectiveness of the Use of a Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the Pathogenetic Therapy of Metabolic-associated Fatty Liver Disease: a Prospective Cohort Study

Status unknown Last updated 12 October 2023

What this trial tests

trial in Metabolic-associated Fatty Liver Disease (MAFLD) in 264 participants. Status unknown.

Timeline

8 February 2023

Primary endpoint
8 February 2025

8 February 2025

Quick facts

Lead sponsor	Kazakh Association of Internal Medicine Specialists
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	264
Start date	8 February 2023
Primary completion	8 February 2025
Estimated completion	8 February 2025
Sites	7 locations across Kazakhstan

Conditions studied

Metabolic-associated Fatty Liver Disease (MAFLD) — all drugs for Metabolic-associated Fatty Liver Disease (MAFLD) →

Sponsor

Kazakh Association of Internal Medicine Specialists

Who can join

Adults 18 to 75, any sex, with Metabolic-associated Fatty Liver Disease (MAFLD). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to learn the effectiveness and safety of the use of Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the pathogenetic therapy of metabolic-associated fatty liver disease (MAFLD)

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Metabolic-associated Fatty Liver Disease (MAFLD)

Currently open trials in the same condition.

NCT06798948 — Effect of the Combined Application of Cynara Scolymus, Silybum Marianum, Curcuma Longa, and Glycyrrhiza Glabra in Improv · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06078722 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kazakh Association of Internal Medicine Specialists
Last refreshed: 12 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06078722.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing